RFM
EPZM

Royal Fund Management’s Epizyme, Inc EPZM Stock Holding History

Royal Fund Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-282
Closed -$3K – 687
2018
Q2 		$3K Hold
282
– – ﹤0.01% 462
2018
Q1 		$5K Hold
282
– – ﹤0.01% 407
2017
Q4 		$3K Hold
282
– – ﹤0.01% 555
2017
Q3 		$5K Hold
282
– – ﹤0.01% 361
2017
Q2 		$4K Hold
282
– – ﹤0.01% 350
2017
Q1 		$4K Hold
282
– – ﹤0.01% 339
2016
Q4 		$3K Buy
+282
New +$2.94K ﹤0.01% 344

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Royal Fund Management's EPZM Position: Q3 2018 in Review

Royal Fund Management sold out of Epizyme, Inc (EPZM) in Q3 2018, closing a stake of 282 shares — an estimated $3K sold.

Royal Fund Management first reported a position in EPZM in Q4 2016 and held it in 7 quarters. The position peaked at $5K in Q1 2018. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2018.

  • Royal Fund Management reported no remaining Epizyme, Inc position as of Q3 2018 after selling out during the quarter.
  • Royal Fund Management sold 282 Epizyme, Inc shares in Q3 2018, an estimated $3K.
  • Royal Fund Management first reported a position in Epizyme, Inc in Q4 2016 and held it in 7 quarters.
  • Royal Fund Management's Epizyme, Inc position peaked at $5K in Q1 2018.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2018.

Based on Royal Fund Management's 13F filing for Q3 2018, filed 7 May 2020.